At the news
? BEARISHIMPACT 7/10 S-4 filed Jul 2, 2026 at 16:03 ET
InMed Pharmaceuticals filed an S-4 registration statement for its merger with Mentari Therapeutics. The deal is structured as a reverse merger in which InMed shareholders will own only ~1.51% of the combined company, while Mentari securityholders (including investors in a $290M pre-closing financing) will own ~98.49%. InMed's legacy business will be wound down, and shareholders will receive contingent value rights (CVRs) with uncertain payoff. The merger is expected to close in Q3 2026, subject to shareholder and regulatory approvals.
- InMed shareholders will own approximately 1.51% of the combined company post-merger.
- Mentari securityholders (including $290M pre-closing financing investors) will own approximately 98.49%.
- InMed is winding down its only revenue-generating segment (BayMedica) and faces going-concern uncertainty.
- InMed shareholders will receive CVRs tied to disposition of legacy assets, which may be valueless.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access